产品
编 号：F109647
产品类型
规格
价格
是否有货
500mg
320
In-stock
1g
400
In-stock
5g
704
In-stock
10g
880
In-stock
结构图
CAS No: 128446-35-5
产品详情
生物活性：
HP-β-CD ((2-Hydroxypropyl)-β-cyclodextrin) is a widely used drug delivery vehicle to improve the stability and bioavailability.
体内研究：
HP-β-CD administration promotes transcription factor EB-mediated clearance of proteolipid aggregates that accumulate due to inefficient activity of the lysosome-autophagy system in cells derived from a patient with a lysosomal storage disorder. Intraperitoneal injection of HP-β-CD significantly improves survival in leukemia mouse models. Systemic administration of HP-β-CD to mice has no significant adverse effects.
体外研究：
Cell treatment with HP-β-CD results in the activation of the transcription factor EB, a master regulator of lysosomal function and autophagy, and in enhancement of the cellular autophagic clearance capacity. HP-β-CD treatment reduces intracellular cholesterol resulting in significant leukemic cell growth inhibition through G2/M cell-cycle arrest and apoptosis. The IC50 values for HP-β-CD after 72 hours exposure are in the range of 3.86-10.09 mM. HP-β-CD also shows anticancer effects against CML cells expressing a T315I BCR-ABL mutation (that confers resistance to most ABL tyrosine kinase inhibitors), and hypoxia-adapted CML cells that have characteristics of leukemic stem cells. In addition, colony forming ability of human primary AML and CML cells is inhibited by HP-β-CD.
HP-β-CD ((2-Hydroxypropyl)-β-cyclodextrin) is a widely used drug delivery vehicle to improve the stability and bioavailability.
体内研究：
HP-β-CD administration promotes transcription factor EB-mediated clearance of proteolipid aggregates that accumulate due to inefficient activity of the lysosome-autophagy system in cells derived from a patient with a lysosomal storage disorder. Intraperitoneal injection of HP-β-CD significantly improves survival in leukemia mouse models. Systemic administration of HP-β-CD to mice has no significant adverse effects.
体外研究：
Cell treatment with HP-β-CD results in the activation of the transcription factor EB, a master regulator of lysosomal function and autophagy, and in enhancement of the cellular autophagic clearance capacity. HP-β-CD treatment reduces intracellular cholesterol resulting in significant leukemic cell growth inhibition through G2/M cell-cycle arrest and apoptosis. The IC50 values for HP-β-CD after 72 hours exposure are in the range of 3.86-10.09 mM. HP-β-CD also shows anticancer effects against CML cells expressing a T315I BCR-ABL mutation (that confers resistance to most ABL tyrosine kinase inhibitors), and hypoxia-adapted CML cells that have characteristics of leukemic stem cells. In addition, colony forming ability of human primary AML and CML cells is inhibited by HP-β-CD.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备